

# Morten Lamberts

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7098274/morten-lamberts-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76  
papers

3,380  
citations

31  
h-index

57  
g-index

79  
ext. papers

4,138  
ext. citations

6.5  
avg, IF

4.93  
L-index

#	Paper	IF	Citations
76	The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes.. <i>Clinical Research in Cardiology</i> , <b>2022</b> , 111, 460	6.1	
75	Protocol for detecting unrecognized sleep apnea in patients with atrial fibrillation by a home-monitoring device: the DAN-APNO study.. <i>BMC Cardiovascular Disorders</i> , <b>2022</b> , 22, 6	2.3	0
74	Bleeding risk following systemic fluconazole or topical azoles in patients with atrial fibrillation on apixaban, rivaroxaban or dabigatran. <i>American Journal of Medicine</i> , <b>2021</b> ,	2.4	2
73	Outcomes of prolonged dual anti-platelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a nationwide registry-based study.. <i>American Heart Journal</i> , <b>2021</b> , 245, 81-81	4.9	0
72	Temporal changes in myocardial infarction diagnostic criteria do not account for the lack of long-term beta-blocker effect on cardiovascular prognosis. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	1
71	Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study. <i>Heart Rhythm O2</i> , <b>2021</b> , 2, 304-308	1.5	6
70	Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study. <i>European Heart Journal</i> , <b>2021</b> , 42, 2899-2908	9.5	2
69	Incidence of acute coronary syndrome during national lock-down: Insights from nationwide data during the Coronavirus disease 2019 (COVID-19) pandemic. <i>American Heart Journal</i> , <b>2021</b> , 232, 146-153	4.9	10
68	Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study. <i>Journal of Ultrasound</i> , <b>2021</b> , 1	3.4	1
67	Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. <i>Heart</i> , <b>2021</b> ,	5.1	4
66	Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. <i>European Heart Journal</i> , <b>2021</b> , 42, 907-914	9.5	14
65	Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007274	7.6	53
64	New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. <i>European Heart Journal</i> , <b>2020</b> , 41, 3072-3079	9.5	53
63	Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> , 6, 292-300	6.4	11
62	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , <b>2020</b> , 142, 2080-2082	16.7	66
61	Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 4189	3.7	39
60	Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. <i>Thorax</i> , <b>2020</b> , 75, 928-933	7.3	4

59	Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2020</b> , 6, 23-31	4.6	6
58	Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 79	8.7	16
57	Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study. <i>BMC Cancer</i> , <b>2019</b> , 19, 1105	4.8	23
56	The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Europace</i> , <b>2019</b> , 21, 572-580	3.9	5
55	Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2019</b> , 124, 629-641	3.1	9
54	CHADS-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 651-658	3.9	43
53	Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , <b>2018</b> , 39, 1698-1705a	9.5	21
52	Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. <i>Europace</i> , <b>2018</b> , 20, e78-e86	3.9	17
51	Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. <i>Heart</i> , <b>2018</b> , 104, 912-920	3.2	12
50	Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	12
49	Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. <i>BMC Cardiovascular Disorders</i> , <b>2018</b> , 18, 91	2.3	12
48	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1790-1800	15.1	30
47	Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 17-26	15.1	34
46	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	74
45	Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2901-2909	15.1	16
44	Infective endocarditis and risk of death after cardiac implantable electronic device implantation: a nationwide cohort study. <i>Europace</i> , <b>2017</b> , 19, 1007-1014	3.9	20
43	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , <b>2017</b> , 38, 907-915	9.5	63
42	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. <i>Scientific Reports</i> , <b>2017</b> , 7, 3347	4.9	25

41	Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 511-521	4.3	4
40	Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study. <i>Circulation</i> , <b>2016</b> , 134, 999-1009	16.7	29
39	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. <i>Scientific Reports</i> , <b>2016</b> , 6, 31477	4.9	68
38	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2016</b> , 37, 1015-23	9.5	68
37	Atrial fibrillation and risk of stroke: a nationwide cohort study. <i>Europace</i> , <b>2016</b> , 18, 1689-1697	3.9	33
36	Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. <i>Europace</i> , <b>2016</b> , 18, 492-500	3.9	11
35	Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1185-93	3	59
34	Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 805-14	27.4	85
33	Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. <i>BMJ, The</i> , <b>2015</b> , 351, h5096	5.9	14
32	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 828-36	12.3	28
31	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , <b>2015</b> , 17, 1215-22	3.9	27
30	Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 516-8	15.1	1
29	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. <i>Europace</i> , <b>2015</b> , 17, 187-93	3.9	135
28	Incidence and influence of hospitalization for recurrent syncope and its effect on short- and long-term all-cause and cardiovascular mortality. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1744-50	3	13
27	Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2689-98	15.1	16
26	Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. <i>Circulation</i> , <b>2014</b> , 129, 1577-85	16.7	204
25	Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1270-80	15.1	46
24	Reply: A persisting dilemma for triple antithrombotic therapy: are we close to finding the correct answer?. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 231-2	15.1	

23	Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 1281-7	2.6	
22	Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. <i>Annals of Internal Medicine</i> , <b>2014</b> , 161, 690-8	8	58
21	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. <i>Europace</i> , <b>2014</b> , 16, 477-84	3.9	69
20	Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2471-82	15.1	205
19	Atrial fibrillation and coronary artery disease: which antithrombotic treatment strategy?. <i>Current Opinion in Cardiology</i> , <b>2014</b> , 29, 595-600	2.1	
18	Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 857-62	5.8	9
17	Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish Nationwide Cohort study. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 717-22	7.6	43
16	Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 832-7	3.2	10
15	Prognosis among healthy individuals discharged with a primary diagnosis of syncope. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 325-32	15.1	59
14	Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 981-9	15.1	265
13	Comparison of incidence, predictors, and the impact of co-morbidity and polypharmacy on the risk of recurrent syncope in patients. <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 1610-5	3	35
12	Automated external defibrillators inaccessible to more than half of nearby cardiac arrests in public locations during evening, nighttime, and weekends. <i>Circulation</i> , <b>2013</b> , 128, 2224-31	16.7	87
11	Accuracy of the ICD-10 discharge diagnosis for syncope. <i>Europace</i> , <b>2013</b> , 15, 595-600	3.9	54
10	Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. <i>Europace</i> , <b>2013</b> , 15, 781-6	3.9	54
9	Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. <i>BMJ Open</i> , <b>2013</b> , 3,	3	130
8	Response to letter regarding article, "Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study". <i>Circulation</i> , <b>2013</b> , 127, e585	16.7	1
7	Evaluation of the CHADS2 risk score on short- and long-term all-cause and cardiovascular mortality after syncope. <i>Clinical Cardiology</i> , <b>2013</b> , 36, 262-8	3.3	21
6	Unexplained Syncope and Diagnostic Yield of Tests in Syncope According to the ICD-10 Discharge Diagnosis. <i>Journal of Clinical Medicine Research</i> , <b>2013</b> , 5, 441-50	2.9	7

5	Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. <i>Circulation</i> , <b>2012</b> , 126, 1185-93	16.7	317
4	Use of nonsteroidal anti-inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 428-34	2.6	14
3	Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. <i>Circulation</i> , <b>2012</b> , 126, 1955-63	16.7	73
2	The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syncope: a Danish nationwide study. <i>Europace</i> , <b>2012</b> , 14, 1506-14	3.9	69
1	Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. <i>Circulation</i> , <b>2011</b> , 123, 2226-35	16.7	229